482 related articles for article (PubMed ID: 18046024)
1. Bolstering the FDA's drug-safety authority.
Schultz WB
N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
[No Abstract] [Full Text] [Related]
2. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
Karst KR
Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
[No Abstract] [Full Text] [Related]
3. Regulatory experts debate FDA's authority.
Young D
Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
[No Abstract] [Full Text] [Related]
4. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
Gass A; Wilson J
Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
[No Abstract] [Full Text] [Related]
5. Assessing supplement safety--the FDA's controversial proposal.
Cohen PA
N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
[No Abstract] [Full Text] [Related]
6. PLIVA v. Mensing: generic consumers' unfortunate hand.
Lee SB
Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
[No Abstract] [Full Text] [Related]
7. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
8. Food and Drug Administration regulation and evaluation of vaccines.
Marshall V; Baylor NW
Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
[TBL] [Abstract][Full Text] [Related]
9. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
O'Reilly JT
Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
[No Abstract] [Full Text] [Related]
10. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
Mello MM; Studdert DM; Brennan TA
N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
[No Abstract] [Full Text] [Related]
11. US lawmakers tackle safety reforms at the FDA.
Zwillich T
Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
[No Abstract] [Full Text] [Related]
12. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
13. Pros and cons of off-label promotion investigations and prosecutions.
Loucks MK
Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
[No Abstract] [Full Text] [Related]
14. Raising the safety bar--the FDA's coxib meeting.
Okie S
N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
[No Abstract] [Full Text] [Related]
15. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
DerGurahian J
Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
[No Abstract] [Full Text] [Related]
16. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
17. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
Dorfman HL; Quinn VM; Brophy EA
Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
[No Abstract] [Full Text] [Related]
18. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
19. PDUFA reauthorization--drug safety's golden moment of opportunity?
Hennessy S; Strom BL
N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
[No Abstract] [Full Text] [Related]
20. Drug-review deadlines and safety problems.
Carpenter D; Zucker EJ; Avorn J
N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]